Background: Lung transplant is the fastest growing solid organ transplant procedure and venous thromboembolism has been described to occur in 8-29% of cases. This is much higher than any other solid organ and the exact incidence has yet to be determined. Risk factors for the development of venous thromboembolic disease (VTE) specific to lung transplant are not fully understood. Purpose: The purpose of this research was to describe the incidence and risk factors for VTE disease during the first year following lung transplant at a busy transplant center in the Southwest United States. Methods: A descriptive retrospective study design was used. Virchow's triad was used as a theoretical model to identify selected variables common to lung transplant in an effort to understand possible risk factors for the development of VTE in this patient population. Consecutive lung transplant cases between June 1, 2013 and May 31, 2014 at St. Joseph's Medical Center in Phoenix, Arizona were retrospectively reviewed and followed for exactly one year following the lung transplant date. Demographic variables, Virchow's triad variables, and variables previously identified in the literature as being risk factors for VTE were collected and analyzed using descriptive, frequency, t-test, chi-square, and logistic regression. Results: The incidence of VTE in this patient population was 25.8% and is consistent with findings from previous studies. Using the constructs of Virchow's triad did not yield any statistically significant predictors for VTE in this patient population. However, lung allocation score (LAS) (OR 1.109, CI 1.038-1.185), body mass index (BMI) (OR 1.362, CI 1.034-1.794), and time on the waitlist (OR 1.094, CI 1.023-1.171) did reach statistical significance as possible predictors for VTE following lung transplant in this patient sample. Conclusions: VTE is a common complication of lung transplant that has a high incidence during the first year following lung transplant. This study did identify LAS, BMI, and time on the waitlist as being possible risk factors for the development of VTE following lung transplant. LAS may be a useful surrogate to determine the risk for VTE in this population.

Comme dans tout cancer, l'association entre myélome multiple et maladie thrombo-embolique veineuse est bien établie. Son incidence au cours du myélome est en moyenne de 10 à 20%. Elle semble plus élevée en cas de myélome de novo et lors de l’utilisation de traitements immunomodulateurs comme le thalidomide. Pourtant, la part de surcroît du risque de thrombose dû à ce traitement n’est pas encore très bien définie. Tout d’abord, nous avons réalisé un bilan de ces pathologies afin de délimiter le champ d’étude grâce à une revue de la littérature. Nous avons ensuite évalué l’incidence de la maladie thrombo-embolique veineuse, identifié les facteurs de risque thrombotique et évalué le classement en groupe de risque des patients présentant un myélome et traités par immunomodulateur grâce à une étude observationnelle, multicentrique, prospective, de la prise en charge des myélomes par les hématologues en France. Par la suite, nous avons réalisé l’analyse médico-économique du seul essai randomisé réalisé à ce jour sur la thrombophylaxie chez les malades présentant un myélome multiple traités par thalidomide en première ligne. Cette étude montre un gain de qualité de vie associé à des économies majeures lors de la prévention de la thrombose par aspirine plutôt que par héparine. Enfin nous avons réalisé 2 études médicales utilisant la génération de thrombine, test biologique de recherche. La première a été effectuée afin d’essayer de prédire les patients qui vont présenter une thrombose. La deuxième a pour but de rechercher l’existence d’une résistance à l’héparine aux doses habituelles utilisées dans cette pathologie / The association between multiple myeloma and venous thromboembolic disease is well established. This incidence in myeloma is on average from 10 to 20%. It appears to be higher in newly diagnosed myeloma and immunomodulatory drugs such as thalidomide might significantly increase the risk. However, the risk of thrombosis due to these treatments is not yet well defined. First, we performed a review of these diseases in order to delimit the field of this study through a literature review. Then, we evaluated the incidence of venous thromboembolic disease in patients with myeloma and treated with immunomodulatory, identified the thrombotic risk factors and evaluated the thrombotic risk assessment based on the physicians choice, through an observational, multicenter, prospective French study. Moreover, we performed the medico-economic analysis of the only randomized trial conducted to date on the thrombophylaxis in patients with multiple myeloma treated with thalidomide in the first line of chemotherapy. This analysis showed a gain in quality of life associated with significant cost savings in the prevention of thrombosis by aspirin rather than heparin. Finally we performed two medical studies using thrombin generation test, a global assay that measures the overall tendency of a plasma sample to form thrombin. The first study was conducted to predict patients who will have thrombosis. The second is performed to know if a heparin resistance with the usual doses in this pathology, exists